FAM210A

Across TCGA pan-cancer cohorts, FAM210A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FAM210A data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FAM210A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM210A expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where FAM210A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.652	0.859	<.001	46	view →
LUAD	DFS	Quartile	III,IV	1.000	0.428	.017	7	view →
UCEC	DFS	Quartile	All	0.753	0.972	.013	6	view →
CCRCC	DFS	Quartile	All	0.575	0.892	.021	4	view →
LSCC	DFS	Median	II,III,IV	0.889	0.684	.025	3	view →
HNSC	DFS	Tertile	IV	0.804	0.558	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FAM210A–PDAC (DFS)

Open the PDAC breakdown →